Nevro Corp Stock News

Upgrades According to JP Morgan, the prior rating for Hello Group Inc (NASDAQ:MOMO) was changed from Neutral to Overweight. For the fourth quarter, Hello Gr had an EPS of $0.36, compared to year-ago q

Company to Host Conference Call on Wednesday, April 26, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , March 29, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device compan

Nevro's (NVRO) Senza HFX iQ SCS system is expected to treat individual patients per their particular treatment requirements.

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.

Nevro Corp (NYSE: NVRO) reported Q4 FY22 sales of $113.8 million, up 11% Y/Y as reported and 12% constant currency, beating the consensus of $113.40 million. Painful diabetic neuropathy (PDN) indica

Nevro (NVRO) delivered earnings and revenue surprises of -10.20% and 0.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Nevro Corporation (NYSE:NVRO ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications and Investor Relations Officer Keith Gros

Nevro (NVRO) delivered earnings and revenue surprises of -10.20% and 0.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and the botto

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Thermo Fisher (TMO) delivered earnings and revenue surprises of 4.05% and 10.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?